GlassScriptPhysician profile
Jasbir S Bisla
NPI 1528058500
$11,793.39
in general payments reported to CMS, 2019-2025
31 companies · $3,211 in 2025
The $3,211 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $696 · 2020: $294 · 2021: $113 · 2022: $1,811 · 2023: $2,581 · 2024: $3,088 · 2025: $3,211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,847 · Education: $32.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,846.81 |
| Education | $32.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,392.44 | 2022-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,413.91 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $956.19 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $900.88 | 2022-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $836.32 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $694.02 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $608.58 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Neurocrine Biosciences, INC. | $548.82 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $474.91 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Axsome Therapeutics, INC. | $368.49 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $344.49 | 2019-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $276.00 | 2022-2025 | Qelbree, Qelbree |
| Abbott Laboratories | $218.75 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $201.13 | 2024-2025 | Cobenfy |
| Avanir Pharmaceuticals, INC. | $181.92 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $178.67 | 2019-2025 | Sublocade, Perseris |
| Almatica Pharma LLC | $172.66 | 2022-2024 | Loreev Xr, Sertraline Hcl |
| Bausch Health US, LLC | $158.73 | 2019-2025 | Aplenzin |
| Medtronic Vascular, INC. | $152.06 | 2020 | |
| Corium, LLC | $135.35 | 2022-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $111.03 | 2022-2023 | Belsomra |
| Sunovion Pharmaceuticals INC. | $82.84 | 2019-2022 | |
| Orexo US, INC. | $80.19 | 2019 | |
| Allergan, INC. | $65.53 | 2020 | |
| Idorsia Pharmaceuticals US INC | $62.06 | 2022-2024 | Quviviq |
| Braeburn INC. | $43.90 | 2025 | Brixadi |
| Tris Pharma INC | $34.90 | 2023 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $33.38 | 2020-2022 | |
| Shire North American Group INC | $28.30 | 2019 | |
| Boston Scientific Corporation | $23.37 | 2025 | Watchman Flx |
| Neos Therapeutics, LP | $13.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasbir Bisla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.